A Canadian startup aims to give the decades-old, hand-performed ELISA test a 21st century upgrade by transforming the humble immunoassay into a high-throughput protein profiling platform. Formerly known as nplex biosciences, Nomic said it has worked with a small number of biopharma partners since its debut in 2018 and is looking to expand.